Medigus Ltd. Series C Warrant
MDGSW
MDGSW was delisted on the 19th of July, 2023.
0 hedge funds and large institutions have $0 invested in Medigus Ltd. Series C Warrant in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 5 closing their positions.
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $10.3K → $0 (-$10.3K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$5.06K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.35K |
| 3 |
SM
Skaana Management
Brooklyn,
New York
|
-$2.31K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$505 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$97 |
MDGSW Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Medigus Ltd. Series C Warrant (MDGSW) for Q3 2023, worth a combined $0 — down 100% from $10.3K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MDGSW and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $5.06K sold.
- 0 institutional investors held Medigus Ltd. Series C Warrant (MDGSW) as of Q3 2023, down from 5 in Q2 2023.
- Funds reported $0 of Medigus Ltd. Series C Warrant stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Medigus Ltd. Series C Warrant positions in Q3 2023 and 5 closed out, a net change of -5 holders.
- The largest Medigus Ltd. Series C Warrant seller in Q3 2023 was Armistice Capital, an estimated $5.06K sold.
Based on aggregated 13F filings for Q3 2023.